glp-1 weight loss drug news november 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio GLP-1 drugs like Ozempic deliver
Description
2021;9:819829.e2
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Busch RS, Kane MP
Furthermore, GLP-1R/glucagon receptor dual agonists are being investigated for the treatment of NAFLD ( The pathogenesis of non-alcoholic fatty liver disease The first phase of NAFLD is characterized by accumulation of fat in the liver (hepatic steatosis), which may progressively lead to NASH (in 520% of patients) with or without concomitant fibrosis
Pancreatitis Ozempics FDA label warns that pancreatitis has been reported in clinical trials, and that anyone experiencing pancreatitis should permanently discontinue using the medication
Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide
